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Vaccine–derived
Poliovirus,
Thailand, 2003
To the Editor: The Polio
Eradication Campaign was started in
Thailand in 1990, and the last polio
case was reported in April 1997.
Although no new cases have been
reported, the Polio Eradication
Campaign continues with 4 preven-
tion strategies: high coverage with 3
doses of oral polio in children <1 year
of age, acute flaccid paralysis surveil-
lance, acute flaccid paralysis case
investigation and response, and
National Immunization Day. Also, the
Ministry of Public Health is prepared
for a national emergency response to
polio importation and circulated vac-
cine–derived poliovirus (1).
In April 2003, a case of acute flac-
cid paralysis was reported from
Phakhao district, Loei province. The
patient was an 18-month-old boy with
normal physical development and
nutritional status. He had a history of
mild asthma and had received bron-
chodilator drugs occasionally during
upper respiratory tract infections in
the past. The patient had been fully
vaccinated. He had received a total of
5 doses of oral polio vaccine: a dose at
2, 4, and 6 months of age, and 2 doses
on National Immunization Day in
December 2002 and January 2003.
On March 27, 2003, while visiting
his grandmother in Phoowiang dis-
trict, Khonkaen province (80 km from
his residence), the patient became ill.
Pneumonia was diagnosed; injected
medications were administered into
his left hip once a day for 3 days. The
patient fully recovered.
On April 1, 2003, cellulitis of finger
developed in the patient. The affected
finger was incised and drained, and
oral antimicrobial drugs were adminis-
tered. The inflammation extended to
his elbow but later subsided.
On April 7, fever, cough, and dys-
pnea developed in the patient. Two
days later, the patient’s left leg
became weak. He was admitted to
Phakhao Hospital with a diagnosis of
pneumonia and with weakness in his
left leg. He was later referred to Loei
Provincial Hospital and acute flaccid
paralysis was diagnosed on April 11.
The muscle weakness progressed
until he could not sit. 
On April 14, the patient was
referred to Khonkaen Regional
Hospital with weakness in both legs
and arms (grade 0–1). Chest radi-
ograph showed perihilar pneumonia.
Cloxacillin, gentamicin, and
immunoglobulin (Ig) (6 g/day × 4
days, patient weight 12 kg) were
administered intravenously to the
patient. He was discharged on April
30 with a diagnosis of Guillain-Barré
syndrome and bacterial pneumonia.
The muscle tone in his right leg and
both arms was grade 3; however, he
could not move his left leg.
Stool samples were collected on
April 11 and 14 and tested for polio at
the Department of Medical Science
(reference laboratory for polio in
Southeast Asia). Poliovirus type 2 was
isolated in the samples; however, the
results were inconclusive for strain
differentiation. The isolates were sent
to the Centers for Disease Control and
Prevention (CDC), USA, for genetic
sequencing, and the result showed
poliovirus type 2 with 1.6% differ-
ence from Sabin strain poliovirus.
Without evidence of recombination
with other nonpolio enterovirus, the
pattern of genomic change was simi-
lar to the change that occurs in
immunodeficient persons. Immune
system testing of the patient on
August 13 showed IgG = 205.9
mg/dL (normal 800–1,700), IgA <5.5
mg/dL (normal 100–490), IgM <16.8
mg/dL (normal 50–320), and IgE
<18.0 mg/dL (normal 0–100). Anti-
bodies to poliovirus type 1, 2, and 3
were 1:16, 1:32, and 1:8, respectively.
Testing of the follow-up stool samples
showed P1/Sabin on August 10. Test
results were negative on October 13,
and results showed nonpolio
enterovirus on November 10 and
December 14. 
Before the large-scale outbreak
response immunization was conduct-
ed, 339 serum samples were collected
from children <5 years of age who
lived in the same district as the patient
or in the same subdistrict as his grand-
mother. Among 153 children who
brought their vaccination records, the
median dose of oral polio vaccine was
7 (range 2–15). All had antibody >1:8
to poliovirus types 1, 2, and 3.
Approximately 2,000 stool samples
were collected from children <5 year
of age who lived in the same district
as the case-patient or his grandmother.
However, after the immunodeficien-
cies vaccine–derived poliovirus was
identified, isolation of the virus was
attempted only from stool samples
from children who lived in the same
subdistrict as the patient. From 223
stool samples, 4 Sabin strain
poliovirus and 32 nonpolio entero-
viruses were isolated. In addition, 2 of
18 stool samples collected in July
from close contacts of the case-patient
were positive for Sabin strain
poliovirus and negative for vaccine–
derived poliovirus. 
The Loei Provincial Health Office
initially did a small-scale response
immunization in 3 adjacent villages
(128 of 129 children) on the day that
the case of acute flaccid paralysis was
reported. Coverage of third dose of
oral polio vaccine in these villages
was 100%. No response immuniza-
tion was conducted at the village in
Khonkaen. On August 8, genetic
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sequencing results showed
vaccine–derived poliovirus; the deci-
sion was made to launch an outbreak
response immunization for 175,000
children  <5 years of age living in
Loei, Khonkaen, and Nongbualampoo
provinces (visited by the patient from
March to August 2003). Two-round
campaigns were conducted in August
and September. The estimated vaccine
coverage was >95%. 
Considering the rate of 1% genom-
ic diversity per year and the immun-
odeficient status of the patient (2), he
should have harbored the vaccine
strain virus since he received the first
dose of routine oral polio vaccine
immunization at 2 months of age, and
the virus was replicated in his gut.
However, why the virus disappeared
in subsequent stool specimens is
unknown. Circulating vaccine–
derived poliovirus is unlikely in this
event, as we found no evidence of
recombination with other nonpolio
enterovirus, high oral polio vaccine
coverage in the community, and no
vaccine–derived poliovirus in other
children.
Although immunoglobulin levels
in this case were low but still
detectable, whether the patient’s ill-
ness was agammaglobulinemia or
hypogammaglobulinemia is uncer-
tain. The detected immunoglobulin
levels, as well as the antibody level to
poliovirus, may be due to intravenous
immunoglobulin (IVIG) the patient
received while hospitalized 4 months
before testing. Since August 2003, the
patient has been on IVIG replacement
therapy after prolonged and repeated
respiratory tract infections.
In retrospect, problems surrounded
this event. First, because of several
attempts to confirm the result, identi-
fication of strain differentiation was
delayed. Second, genetic sequencing
was delayed because of a communica-
tion gap associated with new bioter-
rorism regulations in the United States
during specimen transfer. Third,
knowledge of a possible immune defi-
ciency in the previously healthy child
was lacking, testing for the patient’s
immune status was delayed. 
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Toscana Virus and
Acute Meningitis,
France 
To the Editor: Sandfly fever
Naples virus, Sandfly fever Sicilian
virus, and Toscana virus (family
Bunyaviridae, genus Phlebovirus)
have been recognized as etiologic
agents of human illnesses in European
countries bordering the Mediterra-
nean Sea. These viruses are responsi-
ble for rapidly resolving diseases with
nonspecific symptoms such as fever
and myalgia. However, infection with
Toscana virus may involve the central
nervous system; severity may range
from aseptic meningitis to menin-
goencephalitis (1). In most cases, ill-
nesses caused by Toscana virus
mimics a flulike syndrome with fever,
photophobia, headache, red eyes, and
stiff neck. Recently, 2 cases of
Toscana virus meningoencephalitis in
patients with unusual symptoms and
life-threatening complications were
described in Italy (2). However,
sequelae have never been reported.
Toscana virus infection is now epi-
demic in Italy and Spain (1,3).
Furthermore, sporadic cases have
been reported in travelers returning
from Italy, Spain, Greece, Portugal,
and the South of France (4–6). The
epidemiology of Toscana virus in
France is still unknown. Although
infections with this virus have been
diagnosed by serologic tests in French
patients and in tourists residing in
southeastern France, this pathogen
has reportedly never been isolated in
France (7,8). Here we describe the
clinical and biologic features of
autochthonous meningitis due to
Toscana virus.
On July 9, 2004, a 57-year-old
woman who had never left the south-
eastern coast of France reported
malaise and vomiting. On hospital
admission, her body temperature was
38.5°C, and clinical examination
showed photophobia and stiff neck.
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